JPWO2019148109A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019148109A5 JPWO2019148109A5 JP2020540432A JP2020540432A JPWO2019148109A5 JP WO2019148109 A5 JPWO2019148109 A5 JP WO2019148109A5 JP 2020540432 A JP2020540432 A JP 2020540432A JP 2020540432 A JP2020540432 A JP 2020540432A JP WO2019148109 A5 JPWO2019148109 A5 JP WO2019148109A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- virus
- recombinant oncolytic
- oncolytic virus
- metabolisms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000160A JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622547P | 2018-01-26 | 2018-01-26 | |
| US62/622,547 | 2018-01-26 | ||
| PCT/US2019/015434 WO2019148109A1 (en) | 2018-01-26 | 2019-01-28 | Expression of metabolic modulators in tumor microenvironment to improve tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000160A Division JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511060A JP2021511060A (ja) | 2021-05-06 |
| JP2021511060A5 JP2021511060A5 (https=) | 2022-02-24 |
| JPWO2019148109A5 true JPWO2019148109A5 (https=) | 2022-02-24 |
Family
ID=67396217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540432A Pending JP2021511060A (ja) | 2018-01-26 | 2019-01-28 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
| JP2024000160A Pending JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000160A Pending JP2024029176A (ja) | 2018-01-26 | 2024-01-04 | 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11786569B2 (https=) |
| EP (1) | EP3720283A4 (https=) |
| JP (2) | JP2021511060A (https=) |
| KR (1) | KR102849901B1 (https=) |
| CN (1) | CN111655845A (https=) |
| AU (1) | AU2019212840B2 (https=) |
| CA (1) | CA3087044A1 (https=) |
| WO (1) | WO2019148109A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| US20220409684A1 (en) * | 2019-11-18 | 2022-12-29 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022047220A1 (en) * | 2020-08-27 | 2022-03-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof |
| CA3197371A1 (en) * | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| CN116286911A (zh) * | 2022-10-21 | 2023-06-23 | 上海鑫湾生物科技有限公司 | 一种响应缺氧环境调控病毒复制的可剪接系统及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252260C (zh) | 2000-07-21 | 2006-04-19 | 上海三维生物技术有限公司 | 肿瘤特异性启动子 |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| KR101542275B1 (ko) * | 2007-11-19 | 2015-08-06 | 트랜스진 에스.에이. | 폭스바이러스성 온콜리틱 벡터 |
| CA2709292A1 (en) * | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
| DK3169341T3 (da) | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| HK1255192A1 (zh) | 2015-09-08 | 2019-08-09 | Sillajen, Inc. | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
| KR102016128B1 (ko) * | 2015-09-21 | 2019-08-29 | 주식회사 엘지화학 | 이차전지용 전극의 제조 방법 및 이에 따라 제조된 이차전지용 전극 |
-
2019
- 2019-01-28 US US16/959,025 patent/US11786569B2/en active Active
- 2019-01-28 AU AU2019212840A patent/AU2019212840B2/en active Active
- 2019-01-28 EP EP19744411.0A patent/EP3720283A4/en active Pending
- 2019-01-28 KR KR1020207020696A patent/KR102849901B1/ko active Active
- 2019-01-28 CN CN201980010099.4A patent/CN111655845A/zh active Pending
- 2019-01-28 WO PCT/US2019/015434 patent/WO2019148109A1/en not_active Ceased
- 2019-01-28 JP JP2020540432A patent/JP2021511060A/ja active Pending
- 2019-01-28 CA CA3087044A patent/CA3087044A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000160A patent/JP2024029176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021511060A5 (https=) | ||
| JP7447232B2 (ja) | アルブミン結合ドメイン融合タンパク質 | |
| Conlon et al. | Cytokines in the treatment of cancer | |
| JP7514231B2 (ja) | 癌を治療するためのプラスミド構築体および使用方法 | |
| JP2021118723A5 (https=) | ||
| Feliciani et al. | Keratinocytes and cytokine/growth factors | |
| EP2016098B1 (en) | Antibody-targeted cytokines for therapy | |
| Wang et al. | In vivo antitumor activity of interleukin 21 mediated by natural killer cells | |
| US7141651B2 (en) | Multiple cytokine protein complexes | |
| Hilton et al. | Distribution and comparison of receptors for leukemia inhibitory factor on murine hemopoietic and hepatic cells | |
| JP2018514199A5 (https=) | ||
| CN117659160A (zh) | 生物相关正交细胞因子/受体对 | |
| JPWO2019148109A5 (https=) | ||
| CN112426438A (zh) | 用于调控酸性环境免疫应答的组合物、其制备方法和用途 | |
| CA3073310A1 (en) | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody | |
| KR20230070256A (ko) | 이중특이성 재조합 단백질 및 이의 용도 | |
| CN110582293A (zh) | 合成因子组合物及使用方法 | |
| WO2020135083A1 (en) | Use of chemokine receptor cxcr5 | |
| Sanchez et al. | Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8 | |
| US20230340052A1 (en) | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof | |
| WO2022087453A1 (en) | Chimeric activation receptors | |
| Westermann et al. | CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity | |
| JPWO2020124274A5 (https=) | ||
| OÈzbek et al. | The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells | |
| Kukita et al. | Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system |